dc.contributor.author |
Izquierdo, Conchita |
dc.contributor.author |
Ciruela, Pilar |
dc.contributor.author |
Hernández, S. |
dc.contributor.author |
García-García, J. J. |
dc.contributor.author |
Esteva, C. |
dc.contributor.author |
Moraga-Llop, F. |
dc.contributor.author |
Díaz-Conradi, A. |
dc.contributor.author |
Martínez-Osorio, J. |
dc.contributor.author |
Solé-Ribalta, A. |
dc.contributor.author |
de Sevilla, M. F. |
dc.contributor.author |
González-Peris, S. |
dc.contributor.author |
Codina, María Gema |
dc.contributor.author |
Planes, A. M. |
dc.contributor.author |
Uriona, S. |
dc.contributor.author |
Campins Martí, Magda |
dc.contributor.author |
Muñoz-Almagro, C. |
dc.contributor.author |
Salleras, L. |
dc.contributor.author |
Domínguez, Ángela |
dc.contributor.author |
Universitat Autònoma de Barcelona |
dc.date |
2020 |
dc.identifier |
https://ddd.uab.cat/record/253054 |
dc.identifier |
urn:10.1017/S0950268820002708 |
dc.identifier |
urn:oai:ddd.uab.cat:253054 |
dc.identifier |
urn:pmcid:PMC7770381 |
dc.identifier |
urn:pmc-uid:7770381 |
dc.identifier |
urn:pmid:33148361 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:7770381 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
Epidemiology and Infection ; Vol. 148 (november 2020) |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by/4.0/ |
dc.subject |
Antimicrobial susceptibility |
dc.subject |
Invasive pneumococcal disease |
dc.subject |
PCV13 vaccine |
dc.subject |
Penicillin resistance |
dc.subject |
Serotype distribution |
dc.subject |
Streptococcus pneumoniae |
dc.title |
Pneumococcal serotypes in children, clinical presentation and antimicrobial susceptibility in the PCV13 era |
dc.type |
Article |
dc.description.abstract |
The aim was to analyse invasive pneumococcal disease (IPD) serotypes in children aged ⩽17 years according to clinical presentation and antimicrobial susceptibility. We conducted a prospective study (January 2012-June 2016). IPD cases were diagnosed by culture and/or real-time polymerase chain reaction (PCR). Demographic, microbiological and clinical data were analysed. Associations were assessed using the odds ratio (OR) and 95% confidence intervals (CI). Of the 253 cases, 34.4% were aged <2 years, 38.7% 2-4 years and 26.9% 5-17 years. Over 64% were 13-valent pneumococcal conjugate vaccine (PCV13) serotypes. 48% of the cases were diagnosed only by real-time PCR. Serotypes 3 and 1 were associated with complicated pneumonia (P < 0.05) and non-PCV13 serotypes with meningitis (OR 7.32, 95% CI 2.33-22.99) and occult bacteraemia (OR 3.6, 95% CI 1.56-8.76). Serotype 19A was more frequent in children aged <2 years and serotypes 3 and 1 in children aged 2-4 years and 5-17 years, respectively. 36.1% of cases were not susceptible to penicillin and 16.4% were also non-susceptible to cefotaxime. Serotypes 14, 24F and 23B were associated with non-susceptibility to penicillin (P < 0.05) and serotypes 11, 14 and 19A to cefotaxime (P < 0.05). Serotype 19A showed resistance to penicillin (P = 0.002). In conclusion, PCV13 serotypes were most frequent in children aged ⩽17 years, mainly serotypes 3, 1 and 19A. Non-PCV13 serotypes were associated with meningitis and occult bacteraemia and PCV13 serotypes with pneumonia. Non-susceptibility to antibiotics of non-PCV13 serotypes should be monitored PI11/02081 and PI11/02345) |